Clinical Trial Update: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Olaparib to enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer has completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Enzalutamide (enzalutamide)
• Olaparib (Olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-10-12